Avatrombopag for the treatment of thrombocytopenia post hematopoietic stem-cell transplantation.

It revealed that CRR (platelet count > 50 × 10 9 /l) of the eltrombopag arm was notably higher than that of the placebo arm (21% versus 0%, p = 0.046), but the difference in ORR between the two arms did not reach statistical significance after the 8-week course of treatment. 22 After an in-depth review of these studies, we found that underlying diseases in most of the patients were hematological malignancies, including AML, ALL, and MDS, whereas there was a higher ratio for non-malignancies like AA and PMF in our study.

also in 111,027 other papers